This website uses cookies

Cookies are small text files that can be used by websites to make a user's experience more secure and to analyze traffic to the site. We use cookies for the following purposes:

- Necessary: Cookies are required to access secure areas of the website and to provide important platform notifications. The site cannot function properly without these cookies
- Statistics: Cookies are used to track device information anonymously to better understand how visitors interact with the website.

This notice applies to the following domains:

The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

Friday, November 30, 2018 7:45 AM - 11:00 AM (Pacific Time)

Join us for a live webcast of our CME-certified Friday Satellite Symposium preceding the 60th American Society of Hematology (ASH) Annual Meeting and Exposition.

Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers (HCPs) involved in the care of patients with multiple myeloma.  
Program Overview 
The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This reflects the heterogeneity of myeloma and underscores the inappropriateness of a one-size-fits-all management approach. Improving patient outcomes requires building on the foundation of current therapies with new agents and combinations. It also requires that clinicians fully understand the nature of the disease so they can provide patients with a more personalized approach to treatment. Oncology HCPs have a growing array of tools at their disposal to favorably influence a patient’s quality and quantity of life at every stage of disease—but they can only take advantage of these tools by remaining current on the latest research and understanding the appropriate timing and strategies for using newer therapies.

This activity features evidence-based presentations interspersed with patient cases designed to reinforce key points. The case studies provide a practical context, helping learners integrate new information and strategies into their practices and better enabling them to assess such factors as patient profile, clinical evidence, and risk-versus-benefit in the quest to achieve the best possible durable response.

Learning Objectives
At the conclusion of this activity, participants should be better able to: 
  • Incorporate the most current imaging procedures, cytogenetics, genomics, and other testing tools to define patient prognosis and risk stratification 
  • Select treatment combinations in the frontline setting based on risk and patient-specific characteristics 
  • Describe the advantages and limitations of measuring minimal residual disease 
  • Identify patients who may benefit from consolidation and/or maintenance therapy 
  • Incorporate the use of novel agent/monoclonal antibody–based regimens for relapsed/refractory patients based on currently available evidence, including patient-specific features and genomics 
  • Evaluate emerging data from clinical trials on oral small-molecule inhibitors and immune-oncology–based treatment regimens 
Accreditation and Credit Designation 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Jointly provided by
Support for this activity has been provided through educational grants from Adaptive Biotechnologies, Amgen, and Celgene Corporation.

Paul G. Richardson, MD— 
Program Co-Chair
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Keith Stewart, MBChB—
Program Co-Chair
Mayo Clinic
Scottsdale, Arizona

Ajai Chari, MD
Icahn School of Medicine at Mount Sinai
New York, New York

C. Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

María-Victoria Mateos, MD, PhD
University Hospital of Salamanca
Salamanca, Spain
Gregory J. Orloff, MD
Virginia Cancer Specialists
Fairfax, Virginia

7:45 AMPre-program Survey

8:00 AMIntroduction and Overview
Paul G. Richardson, MD and A. Keith Stewart, MBChB—Program Co-Chairs

8:15 AMCase Study 1
Gregory J. Orloff, MD

8:30 AMMaximizing the Treatment Response—The Role of Induction Selection, ASCT, and MRD
C. Ola Landgren, MD, PhD

8:45 AMProlonging Therapy: Benefits and Risks
Maria-Victoria Mateos, MD

9:00 AMCase Study 2
Gregory J. Orloff, MD

9:15 AMMultiple Myelomas: Detecting Subtypes and How to Treat Them 
A. Keith Stewart, MBChB

9:30 AMPanel Discussion 1

9:45 AMCase Study 3
Gregory J. Orloff, MD

10:00 AMSequencing Treatments in the Relapsed Setting
Ajai Chari, MD

10:15 AMImmuno-Oncology Strategies on the Horizon: Vaccines, CAR T Cells, BiTEs, and New Monoclonal Antibodies
Paul G. Richardson, MD

10:30 AMConcluding Remarks, Community Case Revisited
A. Keith Stewart, MBChB and Paul G. Richardson, MD

10:40 AMQuestions and Answers

  *Note all times are listed in PST 
Already Registered? Log In Now
Complete this form to register for the webcast.
(* indicates required field)